After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml solution, as well as a 120 mg/1.7 ml solution in a single-dose vial.
In addition to financial support, the program promotes community-based health care, such as vaccinations, medication therapy management and health screenings.